Company news
Lixte Biotechnology Holdings, Inc. news in 2026
Lixte Biotechnology Holdings, Inc.'s news releases, calls and decks from 2026, newest first.
LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD
July 6, 2026
LIXTE Joins Russell Microcap Index
June 26, 2026
LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026
June 18, 2026
LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)
June 12, 2026
LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth
June 3, 2026
LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors
June 1, 2026
LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update
May 14, 2026
LIXTE Biotechnology Holdings (LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape
April 20, 2026
LIXTE Biotechnology (LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference
April 13, 2026
Lixte Biotech Holdings (LIXT) Advances Precision Oncology Strategy With LB-100, Expands Clinical and Strategic Partnerships
April 10, 2026
LIXTE Biotechnology Holdings (LIXT) Files 2025 Form 10-K, Highlights Transformational Year
April 2, 2026
LIXTE Biotechnology (LIXT) Has the World's Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes
April 1, 2026
LIXTE Biotechnology (LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials
March 31, 2026
LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year
March 30, 2026
Lixte Biotech (LIXT) Advances Precision Oncology With LB-100, Strengthens Position Through Liora Technologies Partnership
March 27, 2026
Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (LIXT) Saw It Coming
March 25, 2026
LIXTE Biotechnology (LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape
March 23, 2026
LIXTE Biotechnology Holdings (LIXT) Adds Innovative LiGHT Therapy to Pipeline
March 10, 2026
LIXTE Biotechnology (LIXT) Advances Lead Compound in Tumor Immunogenicity Research
March 9, 2026
LIXTE Biotechnology (LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary
February 18, 2026
LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary
February 18, 2026
LIXTE Biotechnology (LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy
February 12, 2026
LIXTE Biotechnology (LIXT) Aligns Liora and LiGHT System With LB-100 to Push Frontier of Cancer Treatment
February 10, 2026
LIXTE Biotechnology (LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment
February 9, 2026
Improving the Odds: How LIXTE Biotechnology (LIXT) Is Working to Make Cancer Therapies More Effective
February 5, 2026
LIXTE Biotechnology Holdings (LIXT) Advances a Novel Approach to Enhancing Cancer Therapy
January 23, 2026
LIXTE Biotechnology Holdings (LIXT) Sponsors Good Health Mind, Body and Soul Summit
January 21, 2026
LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29
January 20, 2026
IBN Initiates Coverage of LIXTE Biotechnology Holdings Inc.
January 13, 2026
LIXTE Biotechnology Holdings (LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK
January 8, 2026
Decks in 2026
- Nomad Power Systems — Investor Presentation (July 2026)
Investor deck · 58 slides · July 2026